Research

Treatment of Tubercular Exudative Pleurisy(TEP) by Mixed Therapy of Chitosan(C), Rifampicin(R) and Isoniazid(H)

 2016.11.26.

Since the latter half of the 1990's TEP has been increased again with the prevalence of tuberculosis(TB) and among the respiratory diseases TEP is recognized as a disease that have a high morbidity and it has been established that the chemical therapy for tuberculosis(TB) is the best for TEP.

Now the multi drug combination therapy of combining tuberculochemotherapy with vitamin compound is the most common in treatment of tuberculous diseases.

This effect is known to restore physiological function such as bacteriostatic ability on mycobacterium tuberculosis(MTB), enhancement of immunocompetence, digestive promoting and action of protecting the liver, but it has not revealed such great effect because of the appearance of drug resistance MTB.

Based on the data that chitosan derived from the shell of lobsters or crabs has an effect of raising antibacterial ability when it is combined with antibiotics, Koryo Medical Department №1, Pyongyang Medical College, Kim Il Sung University have intensified the study of the combination of C(Chitosan).R(Rifampicin).H(Isoniazid).

The results showed that the complex of C.R.H has a stronger inhibitive ability than the complex of R.H on the standard TB colony of H37RV and TB colony separated from the samples of patients with TB.

And the complex of C.R had a stronger antibacterial abilities than R on Staphylococcus 209-P, Escherichia coli O111, Pseudomonas aeruginosaⅡ-3, Bacillus subtills ATCC6633 and their persistence.

Then we examined the mixture of C.H.R to have effect on the liver function

In this course we have been found that this compound has no effect on the levels of serum enzymes and biosynthetic function of the liver.

On the basis of the above mentioned results we have treated TEP by combining chitosan with R.H of lower doses than the doses in treatment for tuberculosis and in consequence the effective rate was higher(92.2%) than that of standard therapy for tuberculosis.(78.2%)

Average therapeutic period of mixed therapy of C.P.H for TEP was reduced significantly(22.6±2.2 days) compared with control group(31.2±2.4days).

From the above- mentioned the combination of C.R.H revealed not only strong bacteriostasis ability and no reaction on the liver but positive effect in the treatment for TEP

Our research on chitosan will continue and hope scientific interchange and to exchange good experiences with each other.